Literature DB >> 17481947

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.

Marco Metra1, Piotr Ponikowski, Kenneth Dickstein, John J V McMurray, Antonello Gavazzi, Claes-Hakan Bergh, Alan G Fraser, Tiny Jaarsma, Antonis Pitsis, Paul Mohacsi, Michael Böhm, Stefan Anker, Henry Dargie, Dirk Brutsaert, Michel Komajda.   

Abstract

Therapy has improved the survival of heart failure (HF) patients. However, many patients progress to advanced chronic HF (ACHF). We propose a practical clinical definition and describe the characteristics of this condition. Patients that are generally recognised as ACHF often exhibit the following characteristics: 1) severe symptoms (NYHA class III to IV); 2) episodes with clinical signs of fluid retention and/or peripheral hypoperfusion; 3) objective evidence of severe cardiac dysfunction, shown by at least one of the following: left ventricular ejection fraction<30%, pseudonormal or restrictive mitral inflow pattern at Doppler-echocardiography; high left and/or right ventricular filling pressures; elevated B-type natriuretic peptides; 4) severe impairment of functional capacity demonstrated by either inability to exercise, a 6-minute walk test distance<300 m or a peak oxygen uptake<12-14 ml/kg/min; 5) history of >1 HF hospitalisation in the past 6 months; 6) presence of all the previous features despite optimal therapy. This definition identifies a group of patients with compromised quality of life, poor prognosis, and a high risk of clinical events. These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives.

Entities:  

Mesh:

Year:  2007        PMID: 17481947     DOI: 10.1016/j.ejheart.2007.04.003

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  74 in total

Review 1.  Therapeutic adjustments in stage D heart failure: challenges and strategies.

Authors:  Emer Joyce; Anju Nohria
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 2.  A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods.

Authors:  Mark Oremus; Robert McKelvie; Andrew Don-Wauchope; Pasqualina L Santaguida; Usman Ali; Cynthia Balion; Stephen Hill; Ronald Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

Review 3.  Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.

Authors:  Marco Metra; Luca Bettari; Valentina Carubelli; Silvia Bugatti; Alessandra Dei Cas; Francesca Del Magro; Valentina Lazzarini; Carlo Lombardi; Livio Dei Cas
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 4.  Effective communication and ethical consent in decisions related to ICDs.

Authors:  Alexander M Clark; Tiny Jaarsma; Patricia Strachan; Patricia M Davidson; Megan Jerke; James M Beattie; Amanda S Duncan; Chantal F Ski; David R Thompson
Journal:  Nat Rev Cardiol       Date:  2011-07-26       Impact factor: 32.419

5.  Occurrence of neuropathies in patients with severe heart failure before and after heart transplantation.

Authors:  Sergio Bagnato; Chiara Minà; Antonino Sant'Angelo; Cristina Boccagni; Caterina Prestandrea; Alessandra Caronia; Francesco Clemenza; Giuseppe Galardi
Journal:  Neurol Sci       Date:  2015-11-14       Impact factor: 3.307

6.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

Review 7.  [The chronic critically ill patient from the cardiologist's perspective].

Authors:  U Janssens; S Reith
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-04-25       Impact factor: 0.840

8.  Emerging Topics Update of the Brazilian Heart Failure Guideline - 2021.

Authors:  Fabiana G Marcondes-Braga; Lídia Ana Zytynski Moura; Victor Sarli Issa; Jefferson Luis Vieira; Luis Eduardo Rohde; Marcus Vinícius Simões; Miguel Morita Fernandes-Silva; Salvador Rassi; Silvia Marinho Martins Alves; Denilson Campos de Albuquerque; Dirceu Rodrigues de Almeida; Edimar Alcides Bocchi; Felix José Alvarez Ramires; Fernando Bacal; João Manoel Rossi Neto; Luiz Claudio Danzmann; Marcelo Westerlund Montera; Mucio Tavares de Oliveira Junior; Nadine Clausell; Odilson Marcos Silvestre; Reinaldo Bulgarelli Bestetti; Sabrina Bernadez-Pereira; Aguinaldo F Freitas; Andréia Biolo; Antonio Carlos Pereira Barretto; Antônio José Lagoeiro Jorge; Bruno Biselli; Carlos Eduardo Lucena Montenegro; Edval Gomes Dos Santos Júnior; Estêvão Lanna Figueiredo; Fábio Fernandes; Fabio Serra Silveira; Fernando Antibas Atik; Flávio de Souza Brito; Germano Emílio Conceição Souza; Gustavo Calado de Aguiar Ribeiro; Humberto Villacorta; João David de Souza Neto; Livia Adams Goldraich; Luís Beck-da-Silva; Manoel Fernandes Canesin; Marcelo Imbroinise Bittencourt; Marcely Gimenes Bonatto; Maria da Consolação Vieira Moreira; Mônica Samuel Avila; Otavio Rizzi Coelho Filho; Pedro Vellosa Schwartzmann; Ricardo Mourilhe-Rocha; Sandrigo Mangini; Silvia Moreira Ayub Ferreira; José Albuquerque de Figueiredo Neto; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-06       Impact factor: 2.000

Review 9.  Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.

Authors:  John R Teerlink; Marco Metra; Valerio Zacà; Hani N Sabbah; Gadi Cotter; Mihai Gheorghiade; Livio Dei Cas
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

10.  Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.

Authors:  Marco Metra; Eric Eichhorn; William T Abraham; Jennifer Linseman; Michael Böhm; Ramon Corbalan; David DeMets; Teresa De Marco; Uri Elkayam; Michael Gerber; Michel Komajda; Peter Liu; Vyacheslev Mareev; Sergio V Perrone; Philip Poole-Wilson; Ellen Roecker; Jennifer Stewart; Karl Swedberg; Michal Tendera; Brian Wiens; Michael R Bristow
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.